Anavex Life Sciences
AVXL
77 hedge funds and large institutions have $58.8M invested in Anavex Life Sciences in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
60% more capital invested
Capital invested by funds: $36.8M → $58.8M (+$22M)
10% more funds holding
Funds holding: 70 → 77 (+7)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0.43% more ownership
Funds ownership: 19.93% → 20.36% (+0.43%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
78% less call options, than puts
Call options by funds: $612K | Put options by funds: $2.84M
Top Buyers
| 1 |
BlackRock
New York
|
+$993K |
| 2 |
Invesco
Atlanta,
Georgia
|
+$503K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$428K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$237K |
| 5 |
State Street
Boston,
Massachusetts
|
+$203K |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$1.28M |
| 2 |
Millennium Management
New York
|
-$375K |
| 3 |
D.E. Shaw & Co
New York
|
-$112K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$98.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$95K |
AVXL Hedge Fund Activity: Q2 2020 in Review
77 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q2 2020, worth a combined $58.8M — up 60% from $36.8M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AVXL positions and 7 closed out — a net gain of 7 holders — while 21 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $993K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.28M sold.
- 77 institutional investors held Anavex Life Sciences (AVXL) as of Q2 2020, up from 70 in Q1 2020.
- Funds reported $58.8M of Anavex Life Sciences stock for Q2 2020, up 60% quarter-over-quarter.
- 14 funds opened new Anavex Life Sciences positions in Q2 2020 and 7 closed out, a net change of +7 holders.
- The largest Anavex Life Sciences buyer in Q2 2020 was BlackRock, an estimated $993K added.
- The largest Anavex Life Sciences seller in Q2 2020 was Renaissance Technologies, an estimated $1.28M sold.
Based on aggregated 13F filings for Q2 2020.